{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:52:00Z","timestamp":1789732320505,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Special research project on monitoring and evaluation of the use of key clinical drugs by the committee for drug evaluation of Chinese research hospital association","award":["Y2023FH-YWPJ03-101"],"award-info":[{"award-number":["Y2023FH-YWPJ03-101"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-5012"],"award-info":[{"award-number":["2024-2-5012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00827-6","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:29:10Z","timestamp":1736414950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients"],"prefix":"10.1186","volume":"26","author":[{"given":"Le","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-2800","authenticated-orcid":false,"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"9","key":"827_CR1","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972\u201388. https:\/\/doi.org\/10.1080\/21645515.2017.1316909.","journal-title":"Hum Vaccin Immunother"},{"key":"827_CR2","doi-asserted-by":"publisher","unstructured":"Brunner HI, Ruperto N, Ramanan AV, et al. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2024;63(9):2535\u201346. https:\/\/doi.org\/10.1093\/rheumatology\/keae180.","DOI":"10.1093\/rheumatology\/keae180"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"152089","DOI":"10.1016\/j.semarthrit.2022.152089","volume":"57","author":"J Sota","year":"2022","unstructured":"Sota J, Vitale A, Lopalco G, et al. Efficacy and safety of tocilizumab in adult-onset still\u2019s disease: real-life experience from the international AIDA registry. Semin Arthritis Rheum. 2022;57:152089. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152089.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"827_CR4","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.berh.2023.101830","volume":"37","author":"JM Springer","year":"2023","unstructured":"Springer JM, Kermani TA. Recent advances in the treatment of giant cell arteritis. Best Pract Res Clin Rheumatol. 2023;37(1):101830. https:\/\/doi.org\/10.1016\/j.berh.2023.101830.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"827_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/1516-3180.2018.0489220719","volume":"137","author":"F Yazilitas","year":"2019","unstructured":"Yazilitas F, Ozdel S, Simsek D, et al. Tocilizumab for juvenile idiopathic arthritis: a single-center case series. Sao Paulo Med J. 2019;137(6):517\u201322. https:\/\/doi.org\/10.1590\/1516-3180.2018.0489220719.","journal-title":"Sao Paulo Med J"},{"key":"827_CR6","doi-asserted-by":"publisher","unstructured":"Diagnosis and treatment protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl). 2020;133(9):1087\u201395. https:\/\/doi.org\/10.1097\/CM9.0000000000000819","DOI":"10.1097\/CM9.0000000000000819"},{"issue":"3","key":"827_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis N, Chirio D, Queyrel-Moranne V, et al. Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Joint Bone Spine. 2017;84(3):369\u201370. https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.008.","journal-title":"Joint Bone Spine"},{"issue":"9","key":"827_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood-2014-08-552000","volume":"125","author":"JH Levy","year":"2015","unstructured":"Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015;125(9):1387\u201393. https:\/\/doi.org\/10.1182\/blood-2014-08-552000.","journal-title":"Blood"},{"issue":"6","key":"827_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/14397595.2018.1428041","volume":"28","author":"H Imamura","year":"2018","unstructured":"Imamura H, Momohara S, Yano K, et al. Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol. 2018;28(6):976\u201380. https:\/\/doi.org\/10.1080\/14397595.2018.1428041.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"827_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","volume":"36","author":"T Okano","year":"2016","unstructured":"Okano T, Inui K, Tada M, et al. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int. 2016;36(3):349\u201357. https:\/\/doi.org\/10.1007\/s00296-015-3379-x.","journal-title":"Rheumatol Int"},{"issue":"4","key":"827_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00296-019-04268-x","volume":"39","author":"D Uskudar Cansu","year":"2019","unstructured":"Uskudar Cansu D, Demirtas E, Andic N, et al. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review. Rheumatol Int. 2019;39(4):743\u201350. https:\/\/doi.org\/10.1007\/s00296-019-04268-x.","journal-title":"Rheumatol Int"},{"issue":"4","key":"827_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694\u2013702. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204345.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"827_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40360-024-00761-7","volume":"25","author":"A Fu","year":"2024","unstructured":"Fu A, Ge F, Wang Y, et al. Development and internal validation of a model for predicting cefoperazone\/sulbactam-associated coagulation disorders in Chinese inpatients. BMC Pharmacol Toxicol. 2024;25(1):41. https:\/\/doi.org\/10.1186\/s40360-024-00761-7.","journal-title":"BMC Pharmacol Toxicol"},{"key":"827_CR14","doi-asserted-by":"publisher","first-page":"943674","DOI":"10.3389\/fphar.2022.943674","volume":"13","author":"B Leng","year":"2022","unstructured":"Leng B, Shen C, Gao T, et al. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China. Front Pharmacol. 2022;13:943674. https:\/\/doi.org\/10.3389\/fphar.2022.943674.","journal-title":"Front Pharmacol"},{"issue":"6","key":"827_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1159\/000532001","volume":"108","author":"C Lin","year":"2023","unstructured":"Lin C, Tan M, Wang D, et al. Safety of Tigecycline in patients on antithrombotic therapy: a single-Center Retrospective Study. Pharmacology. 2023;108(6):540\u20139. https:\/\/doi.org\/10.1159\/000532001.","journal-title":"Pharmacology"},{"issue":"2","key":"827_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"827_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.crad.2016.12.005","volume":"72","author":"XK Niu","year":"2017","unstructured":"Niu XK, He WF, Zhang Y, et al. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer. Clin Radiol. 2017;72(6):458\u201364. https:\/\/doi.org\/10.1016\/j.crad.2016.12.005.","journal-title":"Clin Radiol"},{"issue":"1","key":"827_CR18","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-023-36246-6","volume":"13","author":"T He","year":"2023","unstructured":"He T, Ling J, Yang J. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep. 2023;13(1):9050. https:\/\/doi.org\/10.1038\/s41598-023-36246-6.","journal-title":"Sci Rep"},{"issue":"5","key":"827_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10067-024-06937-0","volume":"43","author":"Q An","year":"2024","unstructured":"An Q, Ma R, Yuan D, et al. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia. Clin Rheumatol. 2024;43(5):1491\u2013501. https:\/\/doi.org\/10.1007\/s10067-024-06937-0.","journal-title":"Clin Rheumatol"},{"key":"827_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2016.02.026","volume":"140","author":"M Souri","year":"2016","unstructured":"Souri M, Mokuda S, Inanami H, et al. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res. 2016;140:100\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2016.02.026.","journal-title":"Thromb Res"},{"issue":"7","key":"827_CR21","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","volume":"19","author":"P Toniati","year":"2020","unstructured":"Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. https:\/\/doi.org\/10.1016\/j.autrev.2020.102568.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"827_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14787210.2020.1800453","volume":"19","author":"K Tomasiewicz","year":"2021","unstructured":"Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Ther. 2021;19(1):93\u2013100. https:\/\/doi.org\/10.1080\/14787210.2020.1800453.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"827_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"827_CR24","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3324\/haematol.2023.284564","volume":"109","author":"M Perl","year":"2024","unstructured":"Perl M, Herfeld K, Harrer DC, et al. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica. 2024;109(9):2969\u201377. https:\/\/doi.org\/10.3324\/haematol.2023.284564.","journal-title":"Haematologica"},{"key":"827_CR25","doi-asserted-by":"publisher","unstructured":"Perl M, Herfeld K, Harrer DC et al. (2024) Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.284564","DOI":"10.3324\/haematol.2023.284564"},{"issue":"19","key":"827_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","volume":"21","author":"A Woods","year":"2000","unstructured":"Woods A, Brull DJ, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21(19):1574\u201383. https:\/\/doi.org\/10.1053\/euhj.1999.2207.","journal-title":"Eur Heart J"},{"issue":"3","key":"827_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.v99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863\u201371. https:\/\/doi.org\/10.1182\/blood.v99.3.863.","journal-title":"Blood"},{"issue":"11","key":"827_CR28","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","volume":"8","author":"B van Zaane","year":"2010","unstructured":"van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483\u201393. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04034.x.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"827_CR29","first-page":"57","volume":"21","author":"P Garzon","year":"1990","unstructured":"Garzon P, Navarro-Ruiz A, Dominguez-Rodriguez J, et al. [Modified procedure for screening anticonvulsants. Re-evaluation of sodium diphenylhydantoin and phenobarbital]. Arch Invest Med (Mex). 1990;21(1):57\u201363.","journal-title":"Arch Invest Med (Mex)"},{"issue":"8","key":"827_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/17474086.2018.1500173","volume":"11","author":"M Levi","year":"2018","unstructured":"Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol. 2018;11(8):663\u201372. https:\/\/doi.org\/10.1080\/17474086.2018.1500173.","journal-title":"Expert Rev Hematol"},{"key":"827_CR31","doi-asserted-by":"publisher","unstructured":"Buzzatti E, Forghieri F, Paterno G, et al. In BCR-ABL1 positive B-Cell Acute lymphoblastic leukemia, steroid therapy induces hypofibrinogenemia. J Clin Med. 2022;11(7). https:\/\/doi.org\/10.3390\/jcm11071776.","DOI":"10.3390\/jcm11071776"},{"issue":"10","key":"827_CR32","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1080\/10428194.2020.1765236","volume":"61","author":"C Gaulin","year":"2020","unstructured":"Gaulin C, Chan A, Derkach A, et al. Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(10):2497\u2013501. https:\/\/doi.org\/10.1080\/10428194.2020.1765236.","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"827_CR33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJM199904013401303","volume":"340","author":"JS Menell","year":"1999","unstructured":"Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994\u20131004. https:\/\/doi.org\/10.1056\/NEJM199904013401303.","journal-title":"N Engl J Med"},{"issue":"10","key":"827_CR34","doi-asserted-by":"publisher","first-page":"e0140564","DOI":"10.1371\/journal.pone.0140564","volume":"10","author":"A Gopalakrishnapillai","year":"2015","unstructured":"Gopalakrishnapillai A, Kolb EA, Dhanan P, et al. Disruption of annexin II \/p11 Interaction suppresses leukemia cell binding, Homing and Engraftment, and sensitizes the leukemia cells to Chemotherapy. PLoS ONE. 2015;10(10):e0140564. https:\/\/doi.org\/10.1371\/journal.pone.0140564.","journal-title":"PLoS ONE"},{"issue":"2","key":"827_CR35","doi-asserted-by":"publisher","first-page":"107062","DOI":"10.1016\/j.ijantimicag.2023.107062","volume":"63","author":"J Guo","year":"2024","unstructured":"Guo J, Wang S, Zhou M, et al. Nomogram for the prediction of tigecycline-induced hypofibrinogenaemia in a Chinese population. Int J Antimicrob Agents. 2024;63(2):107062. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107062.","journal-title":"Int J Antimicrob Agents"},{"key":"827_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/IDR.S388438","volume":"16","author":"Z Li","year":"2023","unstructured":"Li Z, Zeng Q, Xu S, et al. Development and validation of a Nomogram for Predicting Tigecycline-related Coagulopathy: a retrospective cohort study. Infect Drug Resist. 2023;16:423\u201334. https:\/\/doi.org\/10.2147\/IDR.S388438.","journal-title":"Infect Drug Resist"},{"key":"827_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325\u201332. https:\/\/doi.org\/10.2147\/TCRM.S302850.","journal-title":"Ther Clin Risk Manag"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00827-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:40:12Z","timestamp":1737369612000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00827-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4924183\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving humans was approved by the Ethics Committee of Chinese PLA General Hospital with a waiver of the requirement for informed consent (S2024-247-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}